Editorial: Towards (cost)effective cardiovascular risk management: Using new drugs vs. the better use of available ones

International Journal of Clinical Practice

Volumn 64, Issue 2, 2010, Pages 138-140

  Shantsila, A ^a   Lip, G Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSLIPIDEMIA; EDITORIAL; GOVERNMENT; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH EDUCATION; HEALTH PROGRAM; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RISK MANAGEMENT; RISK REDUCTION; SALT INTAKE; STROKE; ECONOMICS; NOTE;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; HUMANS;

EID: 72449144884     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02233.x     Document Type: Editorial

References (20)

1. World Health Organization (WHO). The World Health Report 2002: Reducing Risks, Promoting Healthy Life. New York : WHO. http://www.who.int/whr/2002/en/ whr02-en.pdf (accessed September 2009).
2. Devabhaktuni M, Bangalore S. Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Vasc Health Risk Manag 2009 5 : 377 387.
3. Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006 113 : e85 151.
4. Murray CJ, Lauer JA, Hutubessy C et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003 361 : 717 725.
5. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008 118 : 576 585.
6. Ward S, Lloyd Jones M, Pandor A et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007 11 : 1 160, iii-iv.
7. Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract 2008 62 : 338 351.
8. Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007 21 : 311 316.
9. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005 43 : 521 530.
10. Spring S, Simon R, van der Loo B et al. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial. Thromb Haemost 2008 99 : 182 189.
11. Rudd P. Compliance with antihypertensive therapy: raising the bar of expectations. Am J Manag Care 1998 4 : 957 966.
12. Hughes M, Lip GY, Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008 99 : 295 304.
13. Deitelzweig SB, Becker R, Lin J, Benner J. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism. Thromb Haemost 2008 100 : 810 820.
14. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004 10 : 144 151.
15. Ambrosioni E. Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmacoeconomics 2001 19 : 337 347. (Pubitemid 32319928)
16. Rizzo JA, Abbott TA, Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Econ 1996 5 : 249 265.
17. De Miguel A, Ibanez B, Badimón JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008 100 : 196 203.
18. Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008 100 : 379 390.
19. Chapman RH, Ferrufino CP, Kowal SL, Classi P, Roberts CS. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs. Int J Clin Pract 2010 64 : 169 181.
20. Côté I, Grégoire JP, Moisan J, Chabot I, Lacroix G. A pharmacy-based health promotion programme in hypertension: cost-benefit analysis. Pharmacoeconomics 2003 21 : 415 428.